Alnylam Reports Phase 1/2 Results For Its Drug Candidate ALN-CC5
June 12, 2015 at 21:03 PM EDT
Shares of Alnlyam ended the day down almost 2% after posting early phase 1/2 results for its drug candidate ALN-CC5.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.